Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN

Key Points

• Jennison Associates LLC increased its stake in Illumina by 19.1% in Q4 and now owns 199,858 shares (about 0.13% of the company) valued at roughly $26.21 million.
• Illumina beat Q1 expectations with non‑GAAP EPS of $1.15 and $1.09B in revenue, raised FY‑2026 EPS guidance to $5.15–$5.30, and the board authorized an additional $1.5B in share repurchases as NovaSeq X demand and clinical sequencing drive growth.
• Analyst sentiment is mixed — consensus is a "Hold" with an average price target of $130.13 — while institutional investors own about 89.4% of shares and an insider sale by SVP Patricia Leckman reduced her stake by 12.68%.

Jennison Associates LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 19.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 199,858 shares of the life sciences company's stock after buying an additional 32,011 shares during the period. Jennison Associates LLC owned 0.13% of Illumina worth $26,213,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ILMN. Board of the Pension Protection Fund acquired a new stake in Illumina in the fourth quarter valued at approximately $26,000. Creative Capital Management Investments LLC boosted its position in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock valued at $26,000 after buying an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Illumina in the fourth quarter valued at approximately $26,000. Quent Capital LLC acquired a new stake in Illumina in the third quarter valued at approximately $29,000. Finally, Quarry LP acquired a new stake in Illumina in the third quarter valued at approximately $32,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Insiders Place Their Bets

In related news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company's stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.90% of the stock is owned by corporate insiders.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q1 beat on both EPS and revenue, with non‑GAAP EPS $1.15 vs. $1.05 consensus and revenue $1.09B (up 4.8% y/y); management raised FY‑2026 EPS guidance to $5.15–$5.30 and updated revenue targets — this underpins the stock strength. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• Positive Sentiment: Management cited surging NovaSeq X demand and growth in clinical sequencing as a primary driver of revenue momentum — a product‑driven acceleration that supports durable top‑line growth. ILMN Q1 deep dive: Clinical sequencing fuels growth as NovaSeq X demand surges
• Positive Sentiment: Board authorized an additional $1.5B in share repurchases, expanding buybacks alongside better margins — a capital‑return boost that can support near‑term EPS and investor sentiment. Illumina lifts 2026 outlook and expands share buybacks
• Neutral Sentiment: Analysts are updating models: JPMorgan raised its price target to $125 but kept a "neutral" rating, reflecting mixed views on near‑term upside despite operational improvements. Analyst Price Target Update
• Negative Sentiment: Even with the PT bump, the $125 target implies a mid‑single‑digit to low‑double‑digit downside from current levels — a reminder that some analysts still see limited valuation upside and room for multiple compression. Analyst Price Target Update

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Illumina from a "hold (c)" rating to a "hold (c-)" rating in a research note on Wednesday. Piper Sandler dropped their price target on shares of Illumina from $195.00 to $170.00 and set an "overweight" rating for the company in a research note on Monday, February 9th. Robert W. Baird set a $137.00 price target on shares of Illumina in a research note on Friday, February 6th. Guggenheim raised their price target on shares of Illumina from $144.00 to $170.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Finally, TD Cowen reaffirmed a "hold" rating on shares of Illumina in a research note on Wednesday, January 7th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $130.13.

Illumina Price Performance

ILMN stock opened at $135.78 on Friday. Illumina, Inc. has a 52-week low of $73.86 and a 52-week high of $155.53. The company has a fifty day moving average price of $125.68 and a 200-day moving average price of $126.43. The company has a market capitalization of $20.63 billion, a P/E ratio of 24.91, a PEG ratio of 2.43 and a beta of 1.42. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.71%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm earned $0.97 earnings per share. Illumina's quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.12 EPS for the current year.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.